摘要
目的探讨血清胆碱酯酶活性检测在糖尿病合并冠心病中的临床应用。方法将随机选择的80例糖尿病合并冠心病患者和80例单纯糖尿病患者,所有患者收治起止时间为2016年1月~2018年1月。采用丁酰硫代碱法检测患者血清胆碱酯酶活性水平,分析患者资料,就其价值进行分析。结果糖尿病合并冠心病组患者CHE水平为(9576.45±237.65)U/L,单纯糖尿病组患者CHE水平为(8280.47±248.74)U/L,两组比较差异有统计学意义(P <0.05)。两组患者各项指标比较如下,糖尿病合并冠心病组患者TC、TG、HDL-C及CRP、MBI等指标与单纯糖尿病足比较,差异有统计学意义(P <0.05)。结论通过检测糖尿病患者CHE水平可对患者是否合并冠心病进行诊断,该项指标也是糖尿病合并冠心病患者预后的一个重要观察指标。
Objective To explore the clinical application of serum cholinesterase activity in diabetic patients with coronary heart disease. Methods A total of 80 diabetic patients with coronary heart disease and 80 patients with simple diabetes mellitus were randomLy selected. All the patients were admitted to the hospital from January 2016 to January 2018. The serum cholinesterase activity level of the patients was detected by S-Butyrylthiocholine iodide, and the value of the patient's data was analyzed. Results The level of CHE in diabetic patients with coronary heart disease was(9576.45 + 237.65) U/L, and the CHE level in the diabetic group was(8280.47 + 248.74) U/L, a Which is a significant difference between the two groups(P < 0.05). The levels of CRP, BMI, TC, TG and HDL-C were positively correlated with the level of CHE(r = 0.4721). Conclusion By detecting the level of CHE in diabetic patients, we can diagnose whether coronary heart disease is combined. This index is also an important observation index for prognosis in diabetic patients with coronary heart disease.
引文
[1]陈琼,吴敏校,陈宏斌等.冠心病患者血液Lp-PLA2、hsCRP及D-二聚体检测的相关性分析[J].国际检验医学杂志,2016,09(2):164-165,168.
[2]赵洁,吴俊,贾玫等.冠心病患者血液脂蛋白相关磷脂酶A2与超敏C反应蛋白及D-二聚体的相关性研究[J].中华检验医学杂志,2014,37(3):227-229.
[3]刘艳秋,解长银,王志伟等.糖尿病合并冠心病患者血清乙酰肝素酶水平变化及意义[J].重庆医学,2017,46(3):396-398.
[4]李基克,魏方,李军等.D-二聚体与Lp(a)联合检测在糖尿病合并冠心病中的应用价值[J].标记免疫分析与临床,2014,21(4):394-395,408.
[5]李瑞机,薛小生,李焕文等.血清糖化血红蛋白和C反应蛋白测定在糖尿病合并冠心病患者中的临床意义[J].检验医学与临床,2016,13(23):3399-3401.
[6]高静媛,杨雨旸,邢磊等.促甲状腺激素与老年糖尿病患者合并冠心病相关性分析[J].中国循证心血管医学杂志,2017,9(6):674-676.
[7]崔兆娜,宁莉,吴万通等.血清胆碱酯酶活性检测在糖尿病合并冠心病临床应用[J].国际检验医学杂志,2016,37(1):40-41,44.
[8]蒋希萌.冠心病患者冠状动脉病变严重程度与冠心病危险因素的相关性分析[J].实用临床医学,2015,35(6):23-24,26.